The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM
Cell · 2026-08 · 189 (17) · 5340-5358.e12
DOI: 10.1016/j.cell.2026.05.026 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cell, 2026-08. Verfasst von Nelson F Freeburg und 49 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Department, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIAID NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median survival of under 15 months and no effective treatment after recurrence. A recent phase 1 trial of intracerebroventricular bivalent chimeric antigen receptor (CAR) T cells in recurrent GBM, registered at ClinicalTrials.gov (NCT05168423), showed promising responses, including tumor reduction and prolonged survival. However, relapse remains common. We performed in-depth profiling of longitudinal cerebrospinal fluid (CSF) and tumor samples from responders and non-responders to characterize immune dynamics following infusion. Our study reveals that, although CAR T cells activate post infusion across all patients, outcomes were defined by divergent remodeling of the endogenous immune landscape. Cytotoxic natural killer cell expansion characterized responders, whereas regulatory T cell expansion and abundant baseline immunosuppressive scavenger myeloid cells characterized non-responders. These findings indicate that host immune cells play a critical role in CAR T cell therapy for GBM, suggesting that combinatorial strategies modulating the endogenous immune compartment could improve next-generation treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology Department, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology, Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center, Cleveland, OH, USA.
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania,…
- Neuroscience Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Department of Neuroscience and Mahoney Institute for Neurosciences, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Förderung
- NIAMS NIH HHS
- NIAID NIH HHS
- NINDS NIH HHS
- NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- INSERM
- National Institutes of Health
Zitieren
APA
Freeburg, N. F., Chafamo, D., Konanur Gopikrishna, G., Murphy, R. M., Peng, J. J., Parthasarathy, S., Dumont, S., Estrada, E. G., Logun, M. T., Sun, Y., Wang, X., Grover, P., Rodriguez, J. L., Zhang, D. L., Park, K., Fu, Y., Ben Hamouda, N., Hernandez-Verdin, I., Lamrani, L., …, & Silverbush, D. (2026). The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell, 189(17), 5340-5358.e12. https://doi.org/10.1016/j.cell.2026.05.026
Vancouver
Freeburg NF, Chafamo D, Konanur Gopikrishna G, Murphy RM, Peng JJ, Parthasarathy S, et al. The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell. 2026;189(17):5340-5358.e12. doi:10.1016/j.cell.2026.05.026
BibTeX
@article{Freeburg2026,
author = {Freeburg, Nelson F and Chafamo, Daniel and Konanur Gopikrishna, Gayathri and Murphy, Regan M and Peng, Jacqueline J and Parthasarathy, Shridhar and Dumont, Sydney and Estrada, Edward G and Logun, Meghan T and Sun, Yusha and Wang, Xin and Grover, Payal and Rodriguez, Jesse L and Zhang, Daniel L and Park, Kristen and Fu, Yao and Ben Hamouda, Nadine and Hernandez-Verdin, Isaias and Lamrani, Lamia and Hicks, Kelly A and Cooper, Natalie A and Ekwegbara, Christina and Bawden, Emma Grace and Waterfall, Joshua J and Fuentealba, Jaime and Alcantara, Marion and Seykora, John T and Prouty, Stephen M and Barrett, David and Banerjee, Esha and Cox, Arin and Assenmacher, Charles-Antoine and Macia, Camilla and Yin, Melinda and Carpenter, Erica L and Ming, Guo-Li and Sautès-Fridman, Catherine and Fridman, Wolf H and Tartour, Eric and Wherry, E John and Amigorena, Sebastian and Fraietta, Joseph A and Nasrallah, MacLean P and Song, Hongjun and Miller, Tyler E and Bagley, Stephen J and O'Rourke, Donald M and Binder, Zev A and Alanio, Cécile and Silverbush, Dana},
title = {The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM},
journal = {Cell},
year = {2026},
volume = {189},
number = {17},
pages = {5340--5358.e12},
doi = {10.1016/j.cell.2026.05.026}
}
EUVIMED